Literature DB >> 22679643

Experience and further development with the Voluntary Harmonization Procedure for multinational clinical trials in the European Union.

Hartmut Krafft, Chantal Bélorgey, Gudrun Szalay.   

Abstract

Mesh：

Year:  2012        PMID： 22679643     DOI： 10.1038/nrd3202-c2

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Hartmut krafft. Interview by Bethan Hughes.

Authors:  Hartmut Krafft
Journal:  Nat Rev Drug Discov       Date:  2010-05-14       Impact factor: 84.694

2.  A sponsor's experience with the Voluntary Harmonization Procedure for clinical trial applications in the European Union.

Authors:  Georgios Amexis; Elmar Schmitt
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694
  2 in total
  4 in total

1.  Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.

Authors:  Maria Alice Franzoi; Marion Procter; Chris Twelves; Noam Ponde; Daniel Eiger; Orianne Emond; Emma Clark; Damien Parlier; Sébastien Guillaume; Linda Reaby; Evandro de Azambuja; Jose Bines
Journal:  Ecancermedicalscience       Date:  2022-04-29

2.  Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities.

Authors:  Tilde Dombernowsky; Merete Hædersdal; Ulrik Lassen; Simon Francis Thomsen
Journal:  BMJ Open       Date:  2017-07-10       Impact factor: 2.692

3.  Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases.

Authors:  Marta Del Álamo; Christoph Bührer; Dirk Fisher; Matthias Griese; Paul Lingor; Giovanni Palladini; Nicolas Sireau; Virginie Hivert; Luca Sangiorgi; Florence Guillot; Juliane Halftermeyer; Lenka Soucková; Kristýna Nosková; Regina Demlová
Journal:  Trials       Date:  2022-09-15       Impact factor: 2.728

4.  Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements.

Authors:  Giorgio Frega; Andrea Palloni; Giuseppe Di Pasquale; Gioconda Saccoccio; Alessandro Rizzo; Elisabetta Poluzzi; Primiano Iannone; Giovanni Brandi
Journal:  Front Pharmacol       Date:  2020-10-28       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.